Melanie M. Scherer

Albstadt, BW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

InViTe2 Retreat: Advancing new approach methodologies in chemical safety testing and drug discovery.

InViTe2 Retreat: Advancing new approach methodologies in chemical safety testing and drug discovery.

Journal: ALTEX
Published: June 30, 2025

Detection of Autophagy in Human Peripheral Blood Mononuclear Cells Using Guava® Autophagy and Flow Cytometry.

Detection of Autophagy in Human Peripheral Blood Mononuclear Cells Using Guava® Autophagy and Flow Cytometry.

Journal: Bio-protocol
Published: June 27, 2025

Heat vs. Fatigue: Hyperthermia as a Possible Treatment Option for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

Heat vs. Fatigue: Hyperthermia as a Possible Treatment Option for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

Journal: International journal of molecular sciences
Published: March 20, 2025

Protection against lethal canine distemper virus infection by a dual epitope-targeting synthetic antibody.

Protection against lethal canine distemper virus infection by a dual epitope-targeting synthetic antibody.

Journal: Nature communications
Published: December 02, 2024

Quantification of Autophagosomes in Human Fibroblasts Using Cyto-ID® Staining and Cytation Imaging.

Quantification of Autophagosomes in Human Fibroblasts Using Cyto-ID® Staining and Cytation Imaging.

Journal: Bio-protocol
Published: April 03, 2024

Neutrophil proteases are protective against SARS-CoV-2 by degrading the spike protein and dampening virus-mediated inflammation.

Neutrophil proteases are protective against SARS-CoV-2 by degrading the spike protein and dampening virus-mediated inflammation.

Journal: JCI insight
Published: July 27, 2023

LRP6 Is a Functional Receptor for Attenuated Canine Distemper Virus.

LRP6 Is a Functional Receptor for Attenuated Canine Distemper Virus.

Journal: mBio
Published: January 16, 2023

Biparatopic sybodies neutralize SARS-CoV-2 variants of concern and mitigate drug resistance.

Biparatopic sybodies neutralize SARS-CoV-2 variants of concern and mitigate drug resistance.

Journal: EMBO reports
Published: October 21, 2021
Showing 1-8 of 8

Last Updated: 09/26/2026